SCHEMBL4677528

SCHEMBL4677528

C[C@H](N)C(=O)NNC(=O)NCCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
MEN1 O00255 1/20 0.58
TSHR P16473 1/20 0.58
ANPEP P15144 1/20 0.54
EPHX1 P07099 2/20 0.54
NPC1 O15118 1/20 0.54
MAPT P10636 1/20 0.54
RAB9A P51151 1/20 0.54
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
POLB P06746 1/20 0.50
OPRM1 P35372 1/20 0.48
EPHX2 P34913 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677539 1.00 KMT2A (0.58) KMT2AMEN1TSHRANPEPEPHX1
SCHEMBL4680916 0.92 CYP2C9 (0.62) KMT2AEPHX1CYP2D6CYP2C9CYP2C19
SCHEMBL4675943 0.88 KDM4E (0.55) KMT2AMEN1TSHRNPC1MAPT
SCHEMBL4676756 0.88 KDM4E (0.55) KMT2AMEN1TSHRNPC1MAPT
SCHEMBL15311172 0.86 KMT2A (0.61) KMT2AMEN1TSHRANPEPEPHX1
SCHEMBL6190815 0.86 KMT2A (0.61) KMT2AMEN1TSHRANPEPEPHX1
SCHEMBL7437248 0.86 KMT2A (0.61) KMT2AMEN1TSHRANPEPEPHX1
SCHEMBL4676692 0.85 SMN1; SMN2 (0.53) KMT2AMEN1ANPEPEPHX1MAPT
SCHEMBL4676219 0.85 SMN1; SMN2 (0.53) KMT2AMEN1ANPEPEPHX1MAPT
Hydrochloric Acid SCHEMBL5967355 0.84 KMT2A (0.59) KMT2AMEN1TSHRANPEPEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP claimed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US claimed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP claimed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO claimed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155803-A1 Protease inhibitors DPP7, DPP9, DPP3 KMT2A 1877/4885MEN1 2989/4885TSHR 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.